CSIOVDB: A microarray gene expression database of epithelial ovarian cancer subtype

Oncotarget

Volumn 6, Issue 41, 2015, Pages 43843-43852

  Tan, Tuan Zea ^a   Yang, He ^a   Ye, Jieru ^a   Low, Jeffrey ^b   Choolani, Mahesh ^b   Peng Tan, David Shao ^a,b,c   Thiery, Jean Paul ^a,d,e   Huang, Ruby Yun Ju ^a,b,e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Database; Microarray gene expression; Molecular subtype; Ovarian cancer

Indexed keywords

ADENINE; CYTOSINE; DNA; GUANINE; THYMINE; TUMOR MARKER;

AGE; ARTICLE; CANCER GRADING; CANCER RESEARCH; COPY NUMBER VARIATION; CSIOVDB; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DNA METHYLATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENETIC DATABASE; HISTOPATHOLOGY; HUMAN; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; OVARY CARCINOMA; OVARY METASTASIS; PERITONEUM CANCER; SURVIVAL RATE; TRANSCRIPTOMICS; UTERINE TUBE CARCINOMA; DNA MICROARRAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM; OVARY TUMOR;

DATABASES, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS;

EID: 84952925950     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5983     Document Type: Article

References (31)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015; 65:87-108.
2. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64:9-29.
3. Jayson GC, Kohn EC, Kitchener HC and Ledermann JA. Ovarian cancer. Lancet. 2014; 384:1376-1388.
4. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Archiv: an international journal of pathology. 2012; 460:237-249.
5. Tan TZ, Miow QH, Huang RY, Wong MK, Ye J, Lau JA, Wu MC, Bin Abdul Hadi LH, Soong R, Choolani M, Davidson B, Nesland JM, Wang LZ, Matsumura N, Mandai M, Konishi I, et al. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO molecular medicine. 2013; 5:983-998.
6. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609-615.
7. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Australian Ovarian Cancer Study G, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14:5198-5208.
8. Gourley C, McCavigan A, Perren T, Paul J, Michie CO, Churchman M, WIlliams A, McCluggage WG, Parmar M, Kaplan RS, Hill LA, Halfpenny IA, O'Brien EJ, Raji O, Deharo S, Davison T, et al. Molecular subgroup of highgrade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacisumab. Journal of Clinical Oncology. 2014; 32:5502.
9. Clinic M. (2014). Ovarian cancer subtypes may predict response to bevacizumab. ScienceDaily).
10. Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang RY and Thiery JP. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO molecular medicine. 2014; 6:1279-1293.
11. Miow QH, Tan TZ, Ye J, Lau JA, Yokomizo T, Thiery JP and Mori S. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene. 2015; 34:1899-1907.
12. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling. 2013; 6:pl1.
13. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012; 2:401-404.
14. Gyorffy B, Surowiak P, Budczies J and Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PloS one. 2013; 8:e82241.
15. Madden SF, Clarke C, Stordal B, Carey MS, Broaddus R, Gallagher WM, Crown J, Mills GB and Hennessy BT. OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets. Molecular cancer. 2014; 13:241.
16. Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY and Qualls CR. Incidence and survival rates for female malignant germ cell tumors. Obstetrics and gynecology. 2006; 107:1075-1085.
17. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM and Silva EG. Grading ovarian serous carcinoma using a two-tier system. The American journal of surgical pathology. 2004; 28:496-504.
18. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I and Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009; 115:1234-1244.
19. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature reviews Cancer. 2002; 2:442-454.
20. Auersperg N, Wong AS, Choi KC, Kang SK and Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocrine reviews. 2001; 22:255-288.
21. Waldron L, Riester M and Birrer M. Molecular subtypes of high-grade serous ovarian cancer: the holy grail? Journal of the National Cancer Institute. 2014; 106.
22. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer cell. 2014; 25:91-101.
23. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. The Journal of clinical investigation. 2013; 123:517-525.
24. Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, Gostout B, Podratz KC, Keeney G, Wang HJ, Hartmann LC, Slamon DJ, et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. Journal of the National Cancer Institute. 2014; 106.
25. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, Wan Y, Zhang W, Shukla SA, Vartanov A, Fernandes SM, Saksena G, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013; 152:714-726.
26. Lim SK, Lee MH, Park IH, You JY, Nam BH, Kim BN, Ro J, Lee KS, Jung SY, Kwon YM and Lee ES. Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome. Cancer research and treatment: official journal of Korean Cancer Association. 2015. doi: 10.4143/crt.2014.262. [Epub ahead of print].
27. de Gramont A, Watson S, Ellis LM, Rodon J, Tabernero J, de Gramont A and Hamilton SR. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nature reviews Clinical oncology. 2015; 12:197-212.
28. George SL. Reducing patient eligibility criteria in cancer clinical trials. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1996; 14:1364-1370.
29. Rustin GJ, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart MJ, Bertelsen K, Stuart G, Cassidy J and Eisenhauer E. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24:45-51.
30. McCall MN, Bolstad BM and Irizarry RA. Frozen robust multiarray analysis (fRMA). Biostatistics. 2010; 11:242-253.
31. Johnson WE, Li C and Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007; 8:118-127.